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Phosphorylation of the aggregate-forming protein alpha-synuclein on serine-129 inhibits its 
DNA-bending properties 
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ABSTRACT 
Alpha-synuclein (aSyn) is a vertebrate protein, normally found within the presynaptic nerve 
terminal and nucleus, which is known to form somatic and neuritic aggregates in certain 
neurodegenerative diseases. Disease-associated aggregates of aSyn are heavily phosphorylated at 
serine-129 (pSyn), while normal aSyn protein is not. Within the nucleus, aSyn can directly bind 









poorly understood. Here we demonstrate using a combination of electrophoretic mobility shift 
assay and atomic force microscopy approaches that both aSyn and pSyn can bind DNA within 
the major groove, in a DNA length-dependent manner and with little specificity for DNA 
sequence. Our data are consistent with a model in which multiple aSyn molecules bind a single 
300 base pair (bp) DNA molecule in such a way that stabilizes the DNA in a bent conformation. 
We propose that serine-129 phosphorylation decreases the ability of aSyn to both bind and bend 
DNA, as aSyn binds 304 bp circular DNA forced into a bent shape, but pSyn does not. Two aSyn 
paralogs, beta- and gamma-synuclein, also interact with DNA differently than aSyn, and do not 
stabilize similar DNA conformations. Our work suggests that reductions in aSyn’s ability to bind 
and bend DNA induced by serine-129 phosphorylation may be important for modulating aSyn’s 
known roles in DNA metabolism, including the regulation of transcription and DNA repair. 
 
INTRODUCTION 
Alpha-synuclein (aSyn) is a 140 amino acid-long protein found in vertebrates, where it is known 
to localize to the presynaptic nerve terminal (1-3) and nucleus (1,4-9). aSyn is linked to genetic 
forms of parkinsonism in families with an autosomal dominant inheritance pattern. The first such 
point mutation found (A53T) was in the N-terminal phospholipid-binding domain (10). Since 
then, five additional point mutations (A30P, E46K, H50Q, G51D, A53E) have been suggested to 
cause parkinsonism (11-17) and all occur within a 24 amino acid stretch of the N-terminal 
phospholipid-binding domain, indicating the potential importance of this region in triggering 
disease. This initial genetic linkage between aSyn and parkinsonism led to the discovery that the 
pathological hallmark of sporadic (non-genetic) Parkinson’s Disease, the Lewy body, is 
composed primarily of misfolded aSyn (18), in a combination of fibrillar and granular 
aggregation states (19,20). A subset of prominent neurodegenerative conditions in addition to 
Parkinson’s Disease, including Dementia with Lewy bodies, Multiple System Atrophy and Pure 
Autonomic Failure, are typified by the formation of aSyn aggregates. This has led to the 
adoption of the term “synucleinopathy” to describe the group of diseases characterized by 
pathological aggregation of aSyn. Interestingly, increased expression of aSyn has been shown to 
occur in certain cancers; most prominently in the skin cancer melanoma (21-23), a cancer with 
increased incidence in Parkinson’s Disease patients (24-29).  
 
aSyn’s roles within the presynaptic terminal have been extensively explored and multiple 
specific functions in regulating chemical neurotransmission within this subcellular compartment 
have been described, including modulating exocytosis (30,31), endocytosis (32,33), SNARE 
complex assembly (34), and vesicle clustering (35-37). Several studies have shown that aSyn 
prefers binding highly curved, negatively charged phospholipid membranes through its N-
terminal domain that associates with the outer leaflet of the convex-curved phospholipid bilayer 
of synaptic vesicles by adopting a complementary, concave-curved alpha-helical structure 
composed of two antiparallel helices (38-40). It is through these interactions with 










In addition to its functions in the presynaptic terminal, aSyn can also localize to the nucleus 
where it is less well studied but has been suggested to modulate several DNA- and RNA-
dependent processes. These include regulation of histone modification (4,41), transcription 
(42,43), rRNA (44) and mRNA (45,46) metabolism. Our recent work also suggests a previously 
unrecognized role for aSyn in modulating DNA double-strand break (DSB) repair (9). Many of 
these potential functions are dependent on aSyn’s ability to bind double-stranded nucleic acids, 
including DNA. Early work demonstrated that aSyn can bind DNA in its supercoiled form (47) 
and that this binding can induce conformational changes both in the protein, increasing alpha-
helical content (48), and in bound DNA, converting it into an altered B form (48,49). aSyn can 
also directly bind a large subset of DNA promoter sequences (7), including the PGC-1a (42) and 
Notch (50) gene promoters, where it appears to often downregulate transcription. NMR 
spectroscopy demonstrates that the same N-terminal domain that binds curved, negatively 
charged phospholipid membranes mediates aSyn’s binding to the phosphate backbone of DNA 
(51). Single molecule techniques have shown that aSyn binding can stretch DNA and increase its 
stiffness (52,53), while fluorescence resonance energy transfer (FRET) assays developed to 
study non-canonical DNA structures show that aSyn stabilizes intermediate states on the 
pathway to DNA hairpin formation (54) and can bind to i-motifs (55). Although this work has 
started to reveal the mechanism of aSyn binding to DNA, important questions remain, including 
the role of potential disease-relevant aSyn posttranslational modifications in this process.  
 
Phosphorylation of aSyn at serine-129 (pSyn) is a well-established marker of pathological forms 
of aSyn aggregates. While <4% of aSyn is phosphorylated at this site in normal brain, within 
Lewy bodies >90% of aSyn bears this posttranslational modification (56). In addition, human 
autopsy studies have shown that pSyn is the most sensitive immunohistochemical marker yet 
developed to detect Lewy body pathology (57). Although pSyn may be important for disease 
pathogenesis, and previous work suggests that aSyn phosphorylation can modulate its nuclear 
localization (51,58,59), little is known about how this phosphorylation may affect aSyn’s DNA 
binding properties. Our previous work suggested that both aSyn and pSyn can bind DNA 
directly, but that phosphorylation can alter the nature of this interaction in potentially important 
ways (9). Given that a detailed understanding of how these two synuclein forms interact with 
DNA is still lacking, here we set out to test the properties of DNA that are important for aSyn 
binding and how serine-129 phosphorylation could modulate synuclein-DNA interactions.  
 
RESULTS 
Alpha-synuclein and S129-phospho alpha-synuclein bind DNA in a DNA length-dependent 
manner 
Our previous work has shown that both aSyn and pSyn can bind 300 bp double-stranded 
DNA, but that aSyn produced multiple bound states, while pSyn produced only a single bound 









pSyn to DNA, we tested the ability of each synuclein to bind DNA of different lengths. We 
found that both aSyn and pSyn bind double-stranded DNA in a length-dependent manner (Fig. 
1A). Increasing concentrations of synuclein incubated with a ladder containing DNA of various 
lengths and analyzed using a 10% polyacrylamide gel EMSA system demonstrated that both 
proteins show little obvious interaction with DNA that is 200 bp in length, while longer DNAs 
are bound and shifted upwards. Close examination of this shift due to synuclein binding revealed 
that at a given synuclein concentration all DNA lengths above a certain critical length were 
bound and shifted upwards, while below this critical length DNA was unbound and there was no 
shift in these bands, and the DNA band in between these two lengths (at or near the critical 
length) exhibited both shifted (bound) and unshifted (unbound) bands (Fig. 1A). The value of 
these critical lengths, where the DNA exhibited both shifted and unshifted bands, decreased with 
increasing synuclein concentration. aSyn produced a range of bound states and, therefore, 
smearing of the signal at higher DNA lengths obscured the changes occurring to specific bands 
in the aSyn EMSA. This smearing did not occur with pSyn. This is consistent with our previous 
work showing that aSyn binding to 300 bp DNA produced a laddering effect due to the presence 
of multiple shifted bound states of different apparent lengths, while pSyn only produced a single 
shifted bound state (9). To understand the DNA length-dependence of these band shifts better, 
without the complication of multiple-length DNA fragments in the same lane, we performed 
similar EMSAs using DNA of only a single length, ranging from 125 to 500 bp. These 
experiments also showed a clear length dependence to aSyn and pSyn DNA binding, with aSyn 
binding DNA better than pSyn at DNA lengths between 125-300 bp (Fig. 1B). The Hill slopes 
for binding of aSyn and pSyn were both positive, suggesting cooperative binding interactions 
between both synuclein forms and DNA, although we did not detect significant differences in the 
amount of cooperativity between aSyn or pSyn binding DNA. Given the relative simplicity of 
interpreting mobility changes with pSyn, due to the lack of smearing at high apparent DNA 
lengths, we also tested the ability of pSyn to shift ladder DNA under different gel conditions. We 
saw similar upward shifts of all DNA fragments above a certain critical length, no change below 
this critical length, and partial binding at or near these critical lengths when performing EMSAs 
with polyacrylamide gel concentrations ranging between 6-20% (Supplementary Fig. 1A). To 
assay binding of aSyn to 300 bp DNA using another parallel technique to EMSA, we performed 
atomic force microscopy (AFM) on surfaces where DNA was applied either without aSyn, or in 
the presence of 57 M aSyn, a concentration where we measure robust aSyn-DNA binding in 
our EMSA experiments. These AFM data show evidence of increased apparent DNA thickness 
and a globular protein signal bound to 300 bp DNA in the condition where aSyn is present 
(Supplementary Fig. 1B), suggesting that aSyn does bind 300 bp double-stranded DNA, as 
previous AFM studies have shown with longer DNA molecules (52). 
The physiologically and pathologically relevant conformations of aSyn are subject to 
debate, and questions remain about the role/s of the unfolded monomeric state (60,61), as well as 
a tetrameric structure that it can also form (62). Its ability to bind DNA resides in the N-terminal 









interactions between positively charged lysine residues in the N-terminal domain and the 
phosphate groups within the DNA backbone (51). This is the same N-terminal region that binds 
curved, negatively charged phospholipid membranes by adopting a discontinuous alpha-helical 
structure containing two anti-parallel curved helices (38-40). The longest of these alpha-helices 
is made up of 48 amino acids (residues 45-92) and is measured to be less than 5 nm in length 
(40). In contrast, a 100 bp double-stranded DNA molecule is ~34 nm, seven times longer than 
the DNA-binding domain of aSyn. These estimates and our data suggest that the length-
dependence of synuclein-DNA binding is not simply due to physical constraints preventing 
binding to shorter-length DNAs.   
 
Alpha-synuclein and S129-phospho alpha-synuclein bind DNA with blunt or 5’ overhanging 
ends with similar affinity 
 We next tested the effect of DNA end structure on aSyn and pSyn binding. We used 300 
bp DNA with either a blunt terminus on both ends or a 300 bp DNA with a 4 base 5’ overhang 
on each end. In our 10% polyacrylamide gel EMSA condition, both aSyn and pSyn bound these 
300 bp DNAs similarly (Fig. 2). This suggests that the nature of the DNA end does not strongly 
influence aSyn and pSyn binding and that synuclein may not be a DNA end-binding protein, but 
rather a protein that binds DNA along its length, potentially in its major or minor groove. 
Similarly, changing the sequence of DNA, varying GC content from 56 to 67%, while keeping 
the length 300 bp, had no significant effect on the amount of or cooperativity of aSyn binding 
(Supplementary Fig. 2A). Varying Tris concentration between 5-30 mM similarly also had no 
significant effects on the amount of or cooperativity of aSyn binding (Supplementary Fig. 2B). 
These data suggest that synuclein is not recognizing very specific DNA sequences when binding, 
rather other aspects of the DNA molecule, such as stiffness or ability to adopt non-B forms, may 
be important. These more global DNA properties can be influenced by sequence, but our data 
suggest that aSyn and pSyn binding does not have a tight specificity for one particular DNA 
sequence. In our experiments we only varied 300 bp DNA GC content between 56-67%, while 
previous work has shown that aSyn does bind 16 bp DNA sequences containing 100% GC 
content tightly, and in the process can change them from B-form to an altered B-form of DNA 
(49). Our data are potentially consistent with this previous result (49), since only lower GC 
content sequences (56-67%) were tested, and it will be interesting in the future to explore the 
effects of wider ranges of GC content on synuclein-DNA binding. To test the importance of 
potential electrostatic interactions between aSyn and DNA in the binding reaction, the ionic 
strength of the composition of our EMSA buffer was increased. This was done by adding 
increasing amounts of the divalent cation Ca2+ to minimize the effect of osmolarity changes 
compared to a monovalent cation of comparable ionic strength. In these experiments, high 
concentrations of Ca2+, around 25 mM, did significantly decrease aSyn-DNA binding 
(Supplementary Fig. 3). This potentially indicates the importance of electrostatic interactions 
between aSyn’s positively charged N-terminal domain and the negatively charged phosphate 










Alpha-synuclein and S129-phospho alpha-synuclein binding to DNA is facilitated by small 
molecules that bind in the minor groove but not the major groove 
 To understand how aSyn and pSyn interact with double-stranded DNA, EMSAs under 
conditions where either the minor groove-binding small molecule Hoechst 33258 or the major 
groove binder methyl green were present were performed. Samples were tested for possible 
interactions between Hoechst and the intercalating SybrTM Gold fluorescent dye used to image 
DNA. Hoechst 33258 at concentrations from 0-16 M had no appreciable effect on SybrTM Gold 
fluorescence from 300 bp DNA (Fig. 3A). The addition of either aSyn or pSyn showed increased 
binding of the respective synuclein to DNA in a Hoechst 33258 dose-dependent manner, as 
evidenced by an increased fraction of shifted DNA (Fig. 3A). In contrast to the minor groove 
binder Hoechst 33258, the major groove binding small molecule methyl green reduced 
fluorescence from SybrTM Gold at higher concentrations, with no appreciable effect between 0-
25 nM, but a large reduction at 500nM, and the abolition of SybrTM Gold fluorescence at 1 M 
(Fig. 3B). The addition of aSyn resulted in no increase in the fraction of shifted DNA at methyl 
green concentrations between 0-25 nM, indicating that methyl green does not promote aSyn-
DNA binding (Fig. 3B). Between 250-500 nM, we did not quantify aSyn-DNA binding given the 
complication that methyl green reduces SybrTM Gold fluorescence at these concentrations. 
However, it was observed that aSyn competes with methyl green and substantially restores 
SybrTM Gold DNA fluorescence at these higher methyl green concentrations (Fig. 3B). Similar 
results were also seen with pSyn with evidence that pSyn was able to compete with methyl green 
even more effectively than aSyn to restore SybrTM Gold DNA fluorescence (Fig. 3B).  
 These data suggest that the minor groove binding agent Hoechst 33258 can alter the 
physical properties of DNA in a way that can promote aSyn and pSyn binding. Previous work 
has suggested that Hoeschst 33258, a bisbenzimide minor groove-binding molecule, can bend 
DNA upon binding (63,64), potentially indicating that the ability of Hoechst 33258 to increase 
aSyn and pSyn DNA binding is related to a preference of synuclein for bent DNA 
conformations. In addition, the competitive interaction between the major groove binder methyl 
green (and not with the minor groove binder Hoechst 33258) with aSyn and pSyn suggests that 
synuclein itself is binding DNA within the major groove and not the minor groove. While the 
exact binding mechanism of SybrTM Gold has not been extensively studied, this dye and other 
members of the class intercalate between base pairs (65). Our data suggest that methyl green (at 
higher concentrations) blocks SybrTM Gold intercalation between base pairs, either by direct 
steric hindrance or by altering the parallel base-stacking interactions that are required for SybrTM 
Gold intercalation. Increasing concentration of aSyn and pSyn appears to compete with methyl 
green binding to the major groove without altering SybrTM Gold intercalation.  
 
Altering DNA concentration, while keeping alpha-synuclein concentration fixed, changes the 










 To understand the differing nature of the bound state/s between aSyn or pSyn with DNA, 
we performed a set of experiments where aSyn concentration was fixed at 57 M and the DNA 
concentration was varied between 0.1-200 nM. At higher DNA concentrations (20-200 nM), 
most DNA signals were found in either the unbound band running at its true 300 bp length or in 
a single discrete shifted band, indicating a single bound state running at an apparent length of 
~600 bp (Fig. 4A). At intermediate DNA concentrations (2-10 nM), the unbound band was not 
detectable and all signal was either in the discrete band at ~600 bp, or in a smear of higher 
apparent lengths (Fig. 4A). At the lowest DNA concentrations (0.1-1 nM), all the signals 
appeared in a single, discrete high apparent length band running at >1517 bp (Fig. 4A). In 
contrast to the aSyn data, with pSyn there was no change in the pattern of binding at any tested 
DNA concentration (0.1-200 nM). At all concentrations, ~60% of the DNA signal was in a 
single, discrete unshifted (unbound) band running at 300 bp and the other ~40% was present in a 
single shifted (bound) band running at ~500 bp (Fig. 4B). 
 
Altering protein concentration, while keeping DNA concentration fixed, changes the nature of 
the bound complex with alpha-synuclein, but this does not happen with S129-phospho alpha-
synuclein  
 We next performed a set of experiments where synuclein protein concentration was 
varied between 0-57 M, while DNA concentration was fixed at either a relatively low (0.1 nM) 
or intermediate (6 nM) concentration. In these experiments, aSyn-DNA binding once again 
exhibited a range of bound states limited on the lower end by a discrete state running at ~600 bp, 
favored at the higher DNA concentration (6 nM) when aSyn concentration was relatively low (2-
29 M) – a low aSyn-to-DNA ratio (Fig. 5A). While at a high aSyn-to-DNA ratio, when DNA 
was at the lower concentration (0.1 nM) and aSyn was relatively high (43-57 M), a single larger 
discrete state was favored, running at >1517 bp (Fig. 5A). At intermediate aSyn-to-DNA ratios, a 
range of bound states between these two limits was observed (Fig. 5A). Once again, this range of 
states was not observed with pSyn, and conditions varying pSyn produced only a single bound 
state running at ~500 bp at high pSyn concentrations (29-57 M, Fig. 5B). 
 
Only alpha-synuclein, and not S129-phospho alpha-synuclein, binds circular DNA 
 Our results varying either DNA or protein concentration, while keeping the other fixed 
(Fig. 4 & 5), are consistent with a model where aSyn and pSyn are both able to bind DNA in at 
least one state which shifts the mobility of the bound complex to run as a discrete band at an 
apparent length of ~500-600 bp. Over the DNA concentration range tested (0.1-200 nM) for both 
synuclein proteins, this single bound state is the only complex formed with pSyn. aSyn, however, 
produces multiple bound states. This range of aSyn-DNA complexes occurs, however, over a 
specific interval when using 300 bp DNA. High DNA concentrations (20-200 nM) favor a single 
discrete state that runs at an apparent length of ~600 bp, while low DNA concentrations (0.1-1 
nM) favor a much higher, but still single discrete state, at an apparent length >1517 bp. At 









that span this range (~600 to >1517 bp). These data suggest a model where pSyn can bind DNA 
as a single monomer (or potentially small multimer) to the DNA molecule, but that only one 
such binding event occurs per DNA molecule. In contrast, aSyn can make a similar one 
synuclein-to-one DNA molecular complex and that is favored at relatively high DNA 
concentrations, but when DNA concentrations are relatively low multiple monomers (or small 
multimers) bind as discrete events along the DNA length. Consistent with this, there is a 
saturation of aSyn-DNA binding, presumably when all possible sites on a single molecule of 
DNA are occupied to create the largest possible bound complex (running at >1517bp). Our 
results are similar to previous work using atomic force microscopy to image aSyn binding to 
linear 1000 bp DNA molecules, where at lower aSyn concentration (0.1 M) aSyn molecules 
bind at discrete sites randomly distributed up and down the DNA molecule. At a higher aSyn 
concentration (40 M), however, the entire DNA molecule was evenly coated with a single layer 
of aSyn (52). In our experiments, at high aSyn-to-DNA ratios, the data are also consistent with 
an increasing number of aSyn molecules binding one DNA molecule up to a saturation point. 
aSyn binding significantly changes the conformation of DNA so that it runs at a much higher 
apparent length (>1517 bp). This suggests that aSyn may be bending DNA into specific shapes, 
potentially circle-like forms, which are known to run much more slowly through polyacrylamide 
gels (66). This kind of bending reaction upon binding is inhibited by phosphorylation at serine-
129 in pSyn, since even at high pSyn-to-DNA ratios pSyn binds DNA in a one-to-one fashion 
that does not further slow its migration through the polyacrylamide gel. 
 Given our data suggesting that synuclein proteins promote DNA bending upon binding 
(Fig. 3) and that multiple aSyn molecules may bend a single DNA molecule into a circle-like 
form (Fig. 4 & 5), we next tested whether synuclein proteins bind to circular DNA molecules 
that are forced by their topology into a bent conformation. We converted the linear 300 bp DNA 
(with 4 base overhangs on each end) used in our previous experiments into a 304 bp circular 
form using T4 ligase, both in the presence and absence of the DNA bending protein HMGB1 
(Fig. 6A-B). To remove any remaining linear DNA and confirm their circular state, we incubated 
this product with either T5 or T7 exonuclease. These data demonstrate the formation of 304 bp 
circular DNA, including an additional specific topoisomer that was only present when circular 
DNA was formed in the presence of HMGB1 (Fig. 6B-C). To further check the circular nature of 
these DNA, we performed negative stain transmission electron microscopy on the linear and 
circular DNA samples. These data show the expected presence of linear and circular forms in 
their respective samples (Fig. 6D). These circular forms run in a polyacrylamide gel system at a 
high apparent length (>1517 bp), consistent with previous work showing that circular DNA is 
much less mobile than its linear counterpart in polyacrylamide gels and that circular topoisomers 
are more compact and therefore migrate somewhat faster than topologically simple circles (66). 
Interestingly, incubation of these 304 bp circular forms with aSyn produced clear evidence of 
binding, with a shift of both the circular and circular topoisomer DNA bands (Fig. 6E-F), and 
shift of the simple circular DNA form created without the presence of HMGB1 (Supplementary 









(Fig. 6E-F, Supplementary Fig. 4). These data suggest that the high apparent length complex 
formed by aSyn binding to linear DNA under conditions that favor this bound state (high aSyn-
to-DNA ratio, Fig. 4A & 5A) may be similar in conformation to circular DNA bound to aSyn, 
since their bound complexes share similar properties, including apparent length, and binding 
dependence on aSyn concentration (Fig. 6F). 
 
Mutant alpha-synuclein and beta- and gamma-synuclein do not bind linear DNA similarly to 
wildtype alpha-synuclein 
 To determine the potential effects of mutations in aSyn on 300 bp linear DNA binding, 
we tested under similar conditions three disease-causing point mutations (A30P, E46K, A53T) 
and a deletion form where the central non-amyloid beta-component (NAC) domain, that is 
important for fibrillar aggregation of the protein, was removed (delta NAC). We tested all 
proteins at a low DNA concentration (1.3 nM) which shows moderate levels of binding when 
aSyn is used (Fig. 7A). All mutant forms of aSyn were capable of binding and shifting DNA, 
although with different efficiencies and to different apparent lengths. Two of the disease-causing 
point mutations (A30P, A53T) were less efficient at binding DNA than wildtype (WT) but did 
shift DNA to a similar apparent length, while the other disease-causing point mutation tested 
(E46K) was more efficient at binding DNA and shifted it to a higher apparent length (Fig. 7A). 
The delta NAC form was also more efficient at binding DNA but shifted it to a lower apparent 
length than WT (Fig. 7A). 
To test the ability of the two aSyn paralogs, beta- and gamma-synuclein (bSyn and gSyn, 
respectively), to bind DNA we next tested all three synuclein proteins under similar conditions. 
We tested all three proteins at an intermediate DNA concentration (4 nM) which shows clear 
binding when aSyn is used (Fig. 7B). Unlike aSyn, however, we did not detect appreciable 
binding of either bSyn or gSyn to DNA (Fig. 7B). We next wanted to test the effect of lowering 
DNA or bSyn concentration on potential binding between these two molecules. Interestingly, 
lowering DNA concentration (0.2-4 nM) while keeping bSyn concentration fixed (57 M) 
showed no obvious change at the higher DNA concentrations, but at the lower DNA 
concentrations, the DNA signal was reduced so that at the lowest DNA concentration (0.2 nM, 
highest bSyn-to-DNA ratio) no DNA signal could be detected at all (Supplementary Fig. 5A). 
A similar phenomenon was seen when DNA concentration was fixed at 0.2 nM and bSyn 
concentration varied (3-57 M), where at the highest bSyn-to-DNA ratio DNA signal was absent 
(Supplementary Fig. 5B). A similar set of results was also obtained when testing the ability of 
gSyn to bind DNA (Supplementary Fig. 6), where the highest gSyn-to-DNA ratios produced a 
loss of DNA signal. The physical interpretation of this loss in DNA signal when either bSyn or 
gSyn are present at a high Syn-to-DNA ratio is not clear. There is no evidence that this is due to 
either DNA trapped in the well or DNA migrating at a much faster speed under these conditions 
(data not shown). This suggests that bSyn and gSyn may be changing the conformation of DNA 
in a way that prevents the SybrTM Gold fluorescence used to detect DNA, potentially by directly 









another non-B form that SybrTM Gold does not bind, as has been previously suggested to occur 
when synuclein binds DNA (48,49). Another possibility is that bSyn and gSyn could be 
degrading DNA via a nuclease function. It has been shown that oxidized aSyn species can act as 
nucleases (67), although in our experiments we do not detect evidence of the DNA degradation 
that would be expected in this case and have also chelated the divalent metal ions required for 
many nucleases to function.  
 
DISCUSSION 
Our data show that both aSyn and pSyn can bind DNA, but do so in a DNA length-dependent 
manner. DNA molecules shorter than ~300 bp are not significantly bound under the conditions 
tested, while DNA longer than this is bound and shifted in our EMSA assay. Interestingly, DNA 
that is ~300 bp long is often only partially bound, producing discrete unshifted (unbound) and 
shifted (bound) bands. DNA sequence or end structure does not strongly modulate this binding, 
arguing that another length-dependent physical property of DNA is important for binding. One 
potential possibility is DNA stiffness. Previous work has shown that DNA >300 bp in length is 
flexible enough to easily bend into a circular form, while DNA <200 bp does not easily form 
circles without the use of specific DNA bending proteins because of its inherent stiffness (68). 
DNA that is ~200-300 bp long is at a length (and stiffness) where unaided circle formation starts 
to be possible. This suggests that the interaction of aSyn and pSyn with DNA may be modulated 
by DNA stiffness in such a way that binding requires a structural change in DNA that cannot 
occur when it is too stiff. Such a structural change could involve DNA bending and our data 
using the bisbenzimide DNA dye Hoechst 33258, a dye known to bend DNA (63,64), suggests 
that DNA bending promotes aSyn and pSyn binding. aSyn is able at high aSyn-to-DNA ratios to 
produce a structurally different complex than at low aSyn-to-DNA ratios. Our data suggest that 
this complex may involve multiple aSyn monomers or multimers binding DNA until all possible 
sites are occupied. The fully saturated complex runs at a much higher apparent length and may 
involve DNA bending into a circle-like state. Serine-129 phosphorylation strongly inhibits the 
formation of this potential circle-like form, and our experiments testing aSyn and pSyn binding 
directly to 304 bp circular DNA are consistent with this interpretation. bSyn and gSyn do not 
bind DNA similarly to aSyn under the conditions we have used. These data suggest that aSyn has 
unique properties among the synuclein family members in terms of its ability to bind DNA and 
stabilize circle-like forms. It also suggests that serine-129 phosphorylation is a potential 
regulatory switch that can inhibit this process. Interestingly, known disease-relevant point 
mutations in alpha-synuclein modulate DNA binding in complicated ways, with A30P and A53T 
reducing binding and E46K increasing binding. Removal of the NAC domain also increases 
DNA binding, but produces a state with a lower apparent length. 
 
It strikes us that 200-300 bp DNA when bent into a circle has a diameter that is ~20-30 nm. This 
is similar to the diameter of a synaptic vesicle found at the nerve terminal to which aSyn is 









terminal domain, which can form two concave-curved antiparallel alpha-helices that associate 
with the convex-curved outer leaflet of the vesicle lipid bilayer (38-40). This highly curved 
phospholipid bilayer of a ~20-40 nm (in diameter) synaptic vesicle is thought to present a 
geometry that strongly favors aSyn binding, compared to other membranous compartments 
found in the terminal that have less curved geometries. The concave-curved antiparallel alpha-
helices in aSyn’s N-terminus are amphipathic, favoring strong interactions between their 
hydrophobic face and the lipid environment within the membrane, and between the twelve 
positively charged lysine residues found on the opposite face (between amino acids 1-80) and the 
membrane’s negatively charged phosphate head groups. Previous work using NMR spectroscopy 
has shown that aSyn binds DNA by interacting with the phosphate backbone, using the same N-
terminal region that binds curved phospholipid membranes (51). Given the comparable 
geometries of a 200-300 bp long DNA molecule bent into a circle and a synaptic vesicle, this 
suggests to us that aSyn may have evolved to bind negatively charged convex surfaces of 
discrete geometries using its N-terminal domain, and does so with both synaptic vesicles and 
DNA in a similar fashion. Using structural data taken from aSyn bound to micelles (composed of 
70:30 mixtures of dodecyl phosphocholine:sodium dodecylsulfate) (40) to make a docking 
model with double-stranded DNA suggests that each N-terminal anti-parallel alpha-helix can fit 
within a major groove so that two consecutive major grooves of DNA are occupied. This model 
positions aSyn’s hydrophobic helix face close to individual DNA bases, and also positions 
several helix lysine residues within proximity of the DNA phosphate backbone, allowing for 
possible electrostatic interactions with the DNA phosphate backbone (Fig. 8A-B, Supplemental 
Figs. 7 & 8). At the presynaptic terminal, aSyn’s binding to negatively charged, curved 
phospholipid surfaces is important for modulating synaptic vesicle cycling and 
neurotransmission (30-34), while in the nucleus it could be important for modulating DNA 
structure-dependent processes where aSyn has been implicated, like transcription (42,43) and 
DSB repair (9). It will be important in the future to test this model in both DNA and spherical 
phospholipid bilayer systems that present negatively charged curved surfaces of the appropriate 
geometry to determine the details of alpha-synuclein binding and whether similarities between its 
binding to DNA and curved phospholipid surfaces exist. 
 
Several studies have tested the effects of serine-129 phosphorylation on aSyn’s membrane-
binding properties. In the context of binding synaptosomal membranes (a mixture of the 
presynaptic vesicle, organelle and plasma membranes), serine-129 phosphorylation did not affect 
the binding of the wildtype aSyn protein, but did increase the membrane binding of the disease-
associated A30P mutation (which has reduced membrane binding compared to wildtype at 
baseline) (69). Work in a micelle model system produced similar results: that serine-129 
phosphorylation did not affect lipid-bound aSyn, but could disrupt long-range N- and C-terminal 
interactions within the protein when it is not lipid-bound (70). This argues that long-range N- and 
C-terminal interactions in the protein occur and can be modulated by phosphorylation. In 









membranes, such as ER, Golgi, and mitochondrial membranes in neurons (71) or plasma 
membranes in yeast (72). In planar lipid nanodisc (73) and unilamellar vesicle (74) systems the 
alpha-synuclein C-terminus was disordered even without serine-129 being phosphorylated. 
Unfortunately, to our knowledge, the potential effects of serine-129 phosphorylation on isolated 
presynaptic vesicles, or model spherical phospholipid bilayer systems with similar chemical 
composition and ~20-40 nm (in diameter) geometry, have not been tested to date. Our data 
showing that aSyn binds 304 bp circular DNA, which has a similar geometry to ~30 nm synaptic 
vesicles, while pSyn does not, lead us to propose a model where high concentrations of aSyn 
favor the formation of circle-like DNA structures (Fig. 8C). We also speculate, based on 
potential analogies between DNA circle and phospholipid vesicle binding, that serine-129 
phosphorylation may reduce aSyn binding to presynaptic vesicles, as it does for circular DNA 
(Fig. 8C). It is possible in disease, where aSyn’s ability to properly bind synaptic vesicles could 
be compromised (35), that a similar deficiency in properly binding and bending DNA also occurs 
and leads to detrimental cellular consequences due to the dysregulation of nuclear processes that 
require these synuclein-DNA interactions. It will be interesting in future work to directly test the 
validity of our proposed model by using other techniques that are complementary to the 
primarily EMSA approaches we have used here. For example, examining the high-resolution 
structure of aSyn bound to linear and circular DNA forms, potentially using X-ray diffraction or 
rapidly advancing cryo-EM approaches, could allow direct visualization of the synuclein-DNA 
complex. Also, since EMSA is a biochemical technique requiring purified components, it cannot 
directly measure synuclein-DNA interactions within the cellular milieu. It will also be important 
in the future to study these interactions using other biophysical and cell biological approaches 
that can assay and measure the potential functional consequences of aSyn binding and bending 
nuclear DNA.  
 
Previous work has also suggested that phosphorylation of aSyn by Polo-like kinases (PLK) can 
play important roles in regulating the amount present in the nucleus, and that the PLK family 
member PLK2 specifically phosphorylates serine-129 in the soluble nuclear fraction (75). This 
effect is likely complicated, however, since either overexpressing PLK2 or PLK3 (58), or 
genetically deleting PLK2 (76), produces data consistent with alpha-synuclein phosphorylation 
at serine-129 by these kinases as promoting export of synuclein from the nucleus and into the 
cytoplasm. In contrast, other work suggests that when synuclein is forced into the nucleus by 
fusing it with a nuclear localization sequence, and then mutated at serine-129 to the un-
phosphorylatable residue alanine, that accumulation in the cytoplasm is promoted (51). Further 
work is required to understand the details of synuclein shuttling between the nuclear and 
cytoplasmic compartments, but these data suggest that the identity of the kinase phosphorylating 
serine-129, or other co-phosphorylation events on other residues of the protein, could be 










Our data suggest a new framework for understanding the role of aSyn in the nucleus and its 
biophysical interactions with the DNA located there. The ability of aSyn to bend DNA into 
distinct circle-like conformations may play a role in how it inhibits transcription from specific 
promoters (7,42,50) and/or facilitates forms of DSB repair (9). Our work also highlights the 
important role of serine-129 phosphorylation in regulating this process, acting as a potential 
switch that causes aSyn to unbind from DNA, and therefore allowing the DNA to relax from a 
circle-like conformation into a more linear state. Further exploration of these processes could 
help elucidate the poorly understood functions of nuclear aSyn and how they may be relevant to 
important forms of neurodegeneration and cancer. 
 
EXPERIMENTAL PROCEDURES  
Reagents 
Electrophoretic mobility shift assay (EMSA) reaction buffers and protein storage buffers 
were formulated using either MilliQ purified H2O or filtered molecular biology grade H2O (0.1 
m filter). pH was determined using a pH meter and adjusted with 1 M HCl or 5 M NaOH 
before vacuum filtration (0.2 m filter). Electrophoresis buffers were made with MilliQ purified 
H2O and 10X TBE or 50X TAE stock solutions. 
 
DNA generation 
300 bp linear and 304 bp circular double-stranded DNAs were created using the 300 bp 
band from a 100 bp ladder (New England Biolabs, cat. # N3231) as the template DNA. After 
each extraction and synthesis step described, constructs were cleaned using the QIAquick PCR 
clean-up kit (Qiagen, cat. # 28104) according to the manufacturer’s protocol. An extra wash step 
and two extra spin steps were added before elution of DNA into buffer in the Qiagen protocol to 
reduce ethanol contamination. The final products were eluted into H2O, 1X TE or Buffer EB 
(Qiagen; 10 mM Tris, pH 8.5) and stored at -20 °C until use. The concentration and purity of 
DNA were determined by obtaining 260/280 nm and 260/230 nm readings with a Nanodrop 
spectrophotometer. 125, 200, 300, 400 and 500 bp linear DNA used for testing length-
dependence and 300 bp DNA with varying GC content were synthesized using gBlocks (IDT).  
 
Gel Extraction 
100 bp DNA ladder (New England Biolabs, cat. # N3231) in 1X Orange Loading Dye (Li-Cor, 
cat. # 927-10100) was separated on a 1.5% TAE agarose gel in 1X TAE at 175 V (2 hr at room 
temperature, RT) in the presence of 1X SybrTM Safe (Invitrogen, cat. # S33102) using the 
QIAquick Gel Extraction Kit (Qiagen, cat. # 28704) using the manufacturer’s recommended 
protocol, with the addition of two extra wash and spin steps to minimize ethanol contamination 
before final elution.  
 









Between 10-100 ng of 300 bp template DNA was added to 1 M of forward and reverse primers 
(IDT, forward: 5' TCGAGCAGGCAGAACGG 3', reverse: 5' TGCCTGGTAGGCGTCC 3') 
using 1X Phusion HF PCR Master Mix with HF Buffer (New England Biolabs, cat. # M0531). 
300 bp linear dsDNA with additional 4 base 5’ overhangs on each end were generated from our 
300 bp template DNA using PCR primers (IDT, forward: 5' 
TTAATGAATTCGAGCAGGCAGAAC 3', reverse: 5' 
AATTAGAATTCTGCCTGGTAGGCGT 3') that created a 320 bp dsDNA with EcoRI 
restriction enzyme sites on each end. When cut with EcoRI (1-16 hr at 37 °C, EcoRI-HF, New 
England Biolabs, cat. # R3101), the 300 bp linear dsDNA with the 4 base 5’ overhanging ends 
was produced and the reaction stopped with Proteinase K treatment (1 hr at 37 °C, New England 
Biolabs, cat. # P8111). All DNA was cleaned using the QIAquick PCR clean-up kit (Qiagen, cat. 
# 28104) before use. 
 
Circular DNA Preparation 
Cleaned 300 bp dsDNA with the 4 base 5’ overhanging ends was created as above and treated 
with T4 ligase (New England Biolabs, cat. # M0202), either in the absence or presence of 
HMGB1 (Biolegend, cat. # 557804), using the manufacturer’s recommended protocol (24 hr at 
37 °C). Ligase reactions were stopped with Proteinase K treatment (1 hr at 37 °C, New England 
Biolabs, cat. # P8111) and then cleaned using the QIAquick PCR clean-up kit (Qiagen, cat. # 
28104). Linear species remaining in the sample were removed using either T5 or T7 exonuclease 
(New England Biolabs, cat. # M0363, M0263) using the manufacturer’s recommended protocol.  
 
Electrophoretic mobility shift assay 
All recombinant proteins used for EMSA experiments were handled according to 
manufacturers’ recommendations. Human aSyn and pSyn proteins (Proteos, cat. # RP-003, RP-
004) and human aSyn, bSyn, gSyn, A30P, E46K, A53T, deltaNAC aSyn (rPeptide, cat. # S-
1001, S-1003, S-1007, S-1005, S-1008, S-1002, S-1015) were stored at -80 °C. Glutathione S-
transferase (GenScript, cat. # Z02039) and DNA were stored at -20 °C. All DNA created using 
the 300 bp template DNA had 260/280 nm readings between 1.8-2.0, and 260/230 nm readings 
between 2.0-2.2. Protein-DNA incubation components were added in the following order: 1) 
buffer master mix, 2) recombinant protein, and 3) DNA. The final EMSA buffer solution 
contains 11 mM Tris, 1 mM EDTA, 50 mM NaCl, pH 8.0-8.5. Incubation occurred for 20 min 
on ice followed by 30 min at RT. For major and minor groove binding dye experiments, 
incubations occurred for an additional 30 min at RT with the indicated DNA binding dye 
(Hoechst 33258, ThermoFisher, cat. # H1398; methyl green, Sigma-Aldrich, cat. # 198080). 
After the addition of 2 µL 10X Orange Loading Buffer (Li-Cor, cat. # 927-10100), samples were 
loaded into 6%, 10%, or 20% polyacrylamide Novex TBE gels (Invitrogen) and run in 1X TBE. 
All gels were post-stained for 30 min at RT on a rotator with 1-10X SybrTM Gold DNA Stain 









Images were acquired using a Fluorchem M (Protein Simple) imaging system and quantified 
using ImageJ (NIH) Gel Analyzing tool.  
aSyn point mutation and deltaNAC EMSA protocol: rPeptide EMSA reactions contain 
10ng of a linear 300bp fragment of DNA that was PCR amplified and cleaned up (Qiagen), 0.5% 
Ficoll 400 (Sigma cat. F4375), 4µL of protein or buffer [20mM Tris-HCl, 200mM NaCl], and 
dH2O to a total volume of 10µL. A master mix of 5% ficoll 400, DNA, and dH2O is added to a 
PCR reaction tube containing diluted protein and/or buffer. The reaction tube is gently flicked to 
mix. 1µL of LICOR 10x Orange loading dye (cat. 92710100) is added to the reaction and 8µL 
loaded per lane of a Novex 10% TBE gel (cat. EC62755BOX). The gel is run in 0.5x TBE buffer 
(Corning, cat. 46-011-CM) at 100V for 70min., post-stained in 1x SYBR Gold (Invitrogen cat. 
S11494) for 15min. and imaged on a FluorChem ProteinSimple imager using the green 547nm 
filter. The gel is then fixed for 30min in 40% methanol, 10% acetic acid, followed by post-
staining overnight with Biorad Bio-Safe Coomassie G-250 Stain (cat. 1610786). After washing 
in dH2O, the gel is imaged on a LICOR Odyssey in the 700 channel. Gels are analyzed using 
ImageJ (NIH) Gel Analyzing tool.  
 
Western blot & Coomassie stain 
6% and 10% polyacrylamide TBE gels were transferred onto a Biodyne™ B Nylon 
Membrane (Thermofisher Scientific, cat. # 77016) at 30-35 V for 1 hour and 15 min on ice in 
0.5X TBE using the Novex X-Cell II Blotting System (Invitrogen). After transfer, membranes 
were washed briefly in H2O and fixed for 30 minutes at RT in Ca
2+/Mg2+-free 1X PBS 
containing 4% paraformaldehyde and 0.1% glutaraldehyde. Post-fixation, membranes were 
washed 3X (10 min each) in Ca2+/Mg2+-free PBS containing 0.1% Triton X-100. Membranes 
were blocked overnight in Odyssey PBS Blocking Buffer (Li-Cor, cat. # 927-40000) and stained 
for 1 hour at RT with Syn1 primary antibody (1:1,000; BD Biosciences, cat. # 610787) and 
overnight at 4 °C with IRDye® 800CW Goat anti-Mouse IgG secondary antibody (1:10,000; Li-
Cor, cat. # 926-32210). Images were acquired using Li-Cor Odyssey CLx Imaging System. After 
DNA imaging, some gels were washed 1X (5 min) in MilliQ H2O and stained in 15-20 mL of 
Coomassie G250 Safestain (Bio-Rad, cat. # 1610786) overnight at 4 °C on a rotator. Gels were 
washed 2X (1 hr, then 2 hrs) in MilliQ H2O. Images were acquired using a Li-Cor Odyssey CLx 
Imaging System. 
 
Transmission electron microscopy 
5 µl of DNA suspensions were deposited onto glow discharged (120 secs 15 mAmp, negative 
mode) carbon formvar 400 Mesh copper grids (Ted Pella 01822-F) for 3 min, rinsed 10 secs in 
water, wicked on Whatman filter paper 1, stained for 3 minutes in freshly prepared 1% (w/v) 
uranyl acetate in water, wicked and air-dried. Samples were imaged at 120 kV on a FEI Tecnai™ 
Spirit TEM system. Images were acquired using the AMT interface on an AMT 12 Megapixel 










Atomic force microscopy 
5 ng of 300 bp linear DNA suspended in the same buffer used for the EMSA assay (see above), 
with the addition of 5 mM MgCl2, was deposited on a mica surface without the presence of aSyn. 
Similar experiments using 57 M aSyn with 5 ng of 300 bp linear DNA (suspended in 3 mM 
HEPES at pH 8.0 with 10 mM NaCl, 2 mM MgCl2) were performed after deposition on silicon 
surfaces. AFM samples were prepared using 10 µL of the DNA solution. First, 5 µL of a 5 mM 
MgCl2 solution was deposited dropwise onto freshly cleaved mica or silicon and dried under a 
clean flux of N2 gas. This was followed by the deposition of 5 µL of the DNA-MgCl2 solution 
onto the surface, which was dried with N2 gas. The sample was then rinsed with NANOpure H2O 
to remove excess salt and loosely bound DNA and dried under N2 gas. The same procedure was 
used for samples containing alpha-synuclein and DNA that were allowed to incubate for 10 
minutes before casting onto the surface. Imaging was performed using Digital Instruments Veeco 
AFM/LFM Instrument (Veeco Metrology group). Rotated monolithic, uncoated silicon AFM 
probes were used with 125 µm tip length, 300 kHz resonant frequency and a 40 Newton/meter 
spring constant model Tap300-G (Ted Pella Inc.). The instrument was operated in tapping mode 
while keeping drive amplitude to a minimum, collecting scans of 2 µm x 2 µm at a slow scan 
frequency of 1.5-2.5 Hz and 512 x 512 scans per line. AFM images were analyzed using Digital 
Instruments software. 
 
Experimental design & statistical analysis 
All quantified values are reported as the mean ± SD. The relevant sample type, number 
(N), and statistical tests used to evaluate significance for each experiment are presented with 
each data set.  
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Figure 1. Alpha-synuclein and phospho-synuclein bind DNA in a DNA length-dependent 
manner. (A) Top: EMSA with increasing alpha-synuclein (aSyn) and serine-129 phosphorylated 
alpha-synuclein (pSyn) concentrations with DNA of different lengths shows an upward shift of 
DNA bands greater than 200 bp at higher synuclein concentrations. Shifts produced by aSyn and 
pSyn of specific bands (within gray rectangles) are enlarged and shown below. Bottom: Larger 
image of aSyn and pSyn EMSA shows upward shift of specific DNA bands longer than 200 bp 
depending on aSyn or pSyn concentration. For example, at 57 M pSyn the 300 bp band exhibits 
both shifted (green arrow) and unshifted (blue arrow) species compared to the 4 M 
concentration, where only an unshifted band (blue arrow) is present. (B) Top: Shifts produced by 
aSyn (left) and pSyn (right) with individual DNA lengths (125, 200, 300, 400, and 500 bp). 
Bottom: Group data show the fraction of different length DNAs shifted by 57 M aSyn or pSyn. 
Both aSyn and pSyn binding to DNA depends on DNA length (aSyn EL50=153 bp, R2=0.986, 
deviation from zero slope p<0.0001, Hill slope=3.1; pSyn EL50=281 bp, R2=0.991, deviation 
from zero slope p<0.0001, Hill slope=6.0; 4-parameter dose-response curve; N=3 gels). aSyn 
produces more shift than pSyn of 125, 200 and 300 bp DNA (shifted fraction: aSyn-125 
bp=0.327±0.015, pSyn=125 bp=0.007±0.012, unpaired t-test p<0.0001; aSyn-200 
bp=0.740±0.010, pSyn=200 bp=0.120±0.104, unpaired t-test p=0.0005; aSyn-300 
bp=0.803±0.025, pSyn=300 bp=0.617±0.050, unpaired t-test p=0.0045; aSyn-400 
bp=0.947±0.012, pSyn=400 bp=0.927±0.015, unpaired t-test p=0.145; aSyn-500 
bp=1.000±0.000, pSyn=500 bp=1.000±0.000; N=3 gels). Points at 0 DNA length set to 0.0 
shifted fraction based on model for fitting purposes. 
 
Figure 2. Alpha-synuclein and phospho-synuclein bind DNA with blunt or 5’ overhanging 
ends with similar affinity. Alpha-synuclein (aSyn, A) and serine-129 phosphorylated alpha-
synuclein (pSyn, B) bind 300 bp DNA with blunt or 300 bp DNA with a 4 base 5’ overhanging 
end on both sides similarly (shifted fraction blunt end at 0-4, 16, 29 and 57 M aSyn: 
0.000±0.000, 0.007±0.012, 0.387±0.110, 0.857±0.006; shifted fraction overhanging ends at 0-14, 
29 and 57 M aSyn: 0.000±0.000, 0.417±0.121, 0.917±0.031; comparison of shifted fraction of 
blunt and overhanging end DNA for each aSyn concentration by paired t-test shows no 
significant differences, p between 0.059-0.423; variable slope dose-normalized response curve; 
N=3 gels, x-axis aSyn concentration on log scale; shifted fraction blunt end at 0-14, 29 and 57 
uM pSyn: 0.000±0.000, 0.250±0.098, 0.607±0.101; shifted fraction overhanging ends at 0-14, 29 
and 57 M pSyn: 0.000±0.000, 0.217±0.188, 0.573±0.161; comparison shifted fraction of blunt 
and overhanging end DNA for each pSyn concentration by paired t-test shows no significant 
differences, p between 0.469-0.604; variable slope dose-normalized response curve; N=3 gels, x-
axis pSyn concentration on log scale).  
 
Figure 3. Alpha-synuclein and phospho-synuclein DNA binding is increased by the minor 









methyl green. (A) Increasing concentrations of the DNA minor groove binder Hoechst 33258 
(0-16 M) does not change the signal generated by DNA (left side of each gel) but does increase 
shifted fraction caused by 14 M alpha-synuclein (aSyn) and serine-129 phosphorylated alpha-
synuclein (pSyn; aSyn Hoechst EC50=21.29 M, R2=0.653, deviation from zero slope p=0.0003, 
3-parameter dose-response curve; N=4 gels; pSyn Hoechst EC50=12.76 M, R2=0.395, 
deviation from zero slope p=0.0002, x-axis Hoechst concentration on log scale). (B) In contrast, 
high concentrations (at 500 nM and above) of the DNA major groove binder methyl green 
decrease intercalation and/or fluorescence of the Sybr dye used to image DNA (left side of aSyn 
and pSyn gels). Addition of 29 M aSyn or pSyn competes with methyl green and partially 
restores Sybr dye fluorescence signal. Methyl green does not affect the shifted fraction of DNA 
in the presence of 29 M aSyn or pSyn at values where it does not reduce Sybr dye fluorescence 
(at 250 nM and less, aSyn: R2=0.205, deviation from zero slope p=0.5473; pSyn: R2=0.748, 
deviation from zero slope p=0.1351; N=3 gels, x-axis methyl green concentration on log scale). 
The 14 and 29 M aSyn and pSyn concentrations were chosen since these produced intermediate 
levels of shift, allowing for detection of possible changes with small-molecule dye addition.  
 
Figure 4. Lowering DNA concentration shifts alpha-synuclein-bound complexes into a 
different state, but this does not happen with phospho-synuclein. (A1) Decreasing 300 bp 
DNA concentration from 200 nM to 0.1 nM with fixed alpha-synuclein (aSyn) concentration (57 
M) produces a change in the apparent length of the complex from to a lower value shift 
(running ~600bp, green arrow) to a higher value shift (running >1517 bp DNA, red arrow). 
Unshifted (unbound) DNA marked by the blue arrow. (A2) Western blot showing aSyn protein 
loaded into each lane. (A3) DNA gel (green) and aSyn western blot (red) localization from the 
same experiment. (A4) Left: Group data showing total shifted fraction as a function of DNA 
concentration (DNA IC50=72.24 nM, R2=0.919, 3-parameter dose-response curve, N=3 gels). 
Right: Shifted fraction of high (>1517 bp) and low (~600 bp) apparent length complexes (high 
length complex DNA IC50=16.26 nM, R2=0.961, 3-parameter dose-response curve, N=2 gels; 
low length complex DNA EC50=5.90 nM, R2=0.842, 3-parameter dose-response curve, N=2 
gels). x-axis DNA concentrations on a log scale. (B1) Decreasing 300 bp DNA concentration 
from 200 nM to 0.1 nM with fixed serine-129 phosphorylated alpha-synuclein (pSyn) 
concentration (57 M) produces no change in the apparent length of the bound complex (running 
~500 bp, green arrow). Unshifted (unbound) DNA marked by the blue arrow. (B2) Western blot 
showing pSyn protein loaded into each lane. (B3) DNA gel (green) and pSyn western blot (red) 
localization from the same experiment. (B4) Left: Group data showing little change in total 
shifted fraction as a function of DNA concentration (DNA EC50=0.38 nM, R2=0.116, 3-
parameter dose-response curve, N=3-4 gels). Right: Shifted fraction of each complex shows no 
detectable high (>1517 bp), and only detectable low (~500 bp) apparent length complexes. x-axis 










Figure 5. Increasing alpha-synuclein concentration shifts alpha-synuclein-bound complexes 
into a different state, but this does not happen with phospho-synuclein. (A1) Decreasing 
alpha-synuclein (aSyn) protein concentration from 57 to 1 M with 300 bp DNA concentration 
fixed at either 0.1 nM (left) or 6 nM (right) produces a change in the apparent length of the 
complex from a higher value shift (running >1517 bp DNA, red arrow) to a lower value shift 
(running ~600 bp, green arrow). Unshifted (unbound) DNA marked by the blue arrow. (A2) 
Western blot showing aSyn protein loaded into each lane. (A3) DNA gel (green) and aSyn 
western blot protein (red) localization from the same experiment. (A4) Group data showing 
shifted fraction as a function of aSyn concentration for the two different fixed DNA 
concentrations. The low DNA concentration curve is left-shifted (aSyn EC50: low DNA 
conc.=0.273 uM, R2=0.619; high DNA conc.=5.846 M, R2=0.977, 3-parameter dose-response 
curve; N=3-4 gels, x-axis aSyn concentration on log scale). (B1) Decreasing serine-129 
phosphorylated alpha-synuclein (pSyn) protein concentration from 57 to 1 M with 300 bp DNA 
concentration fixed at either 0.1 nM (left) or 6 nM (right) produces only a complex with an 
apparent length of ~500 bp (green arrow) at the higher pSyn concentrations. Unshifted 
(unbound) DNA marked by the blue arrow. (B2) Western blot showing pSyn protein loaded into 
each lane. (B3) DNA gel (green) and pSyn western blot (red) localization from the same 
experiment. (B4) Group data showing a similar shifted fraction as a function of pSyn 
concentration for the two different fixed DNA concentrations (pSyn EC50: low DNA 
conc.=27.34 M, R2=0.779; high DNA conc.=32.49 M, R2=0.981, 4-parameter dose-response 
curve; N=3 gels, x-axis pSyn concentration on log scale). 
 
Figure 6. Alpha-synuclein binds 304 bp circular DNA forms and phospho-synuclein does 
not. (A) Agarose gel electrophoresis shows 300 bp linear DNA (with additional 4 base 5’ 
overhanging ends on each side) treated with no T4 ligase, T4 ligase, or T4 ligase and the DNA 
bending protein HMGB1. The untreated sample only contains 300 bp linear DNA. The T4 ligase 
treated sample contains 300 bp & 604 bp linear DNA and 304 bp circular forms (which run 
faster than their linear counterpart in the agarose gel system). The sample treated with T4 ligase 
and HMGB1 shows increased formation of 304 bp circular DNA forms. (B) Polyacrylamide 
(6%) gel electrophoresis shows 300 bp linear DNA treated with no T4 ligase, T4 ligase, or T4 
ligase and the DNA bending protein HMGB1. The untreated sample only contains 300 bp linear 
DNA. The T4 ligase treated sample contains 300 bp & 604 bp linear DNA and 300 bp circular 
forms (which run slower than their linear counterpart in the polyacrylamide gel system). The 
sample treated with T4 ligase and HMGB1 shows the formation of a new 304 bp circular DNA 
topoisomer form (which runs somewhat faster due to its more compact nature). (C) 300 bp linear 
DNA first treated with T4 ligase and HMGB1 (to produce some circular forms, as in B), then 
with either T7 or T5 exonuclease to remove linear DNA molecules, shows the expected 
resistance to exonuclease treatment of the 304 bp circular DNA forms. (D) Top: Negative stain 
transmission electron microscopy of 300 bp linear DNA without ligase treatment shows linear 









T4 ligase shows 304 bp circular molecules with the expected diameter (~30 nm). Scale bar 25 
nm. (E) Only aSyn, and not pSyn, causes a shift of the 304 bp circular DNA forms created in the 
presence of HMGB1 (red arrows: circular form, orange arrows: circular topoisomer) to a higher 
apparent length (purple arrow). (F) Left: Synuclein concentration dependence of shift of circular 
DNA forms created in the presence of HMGB1 shows that only aSyn causes a shift at these 
concentrations and pSyn does not. Right: Group data showing shifted fraction of 304 bp DNA 
circles and circular topoisomers as a function of synuclein concentration (aSyn: EC50 circular 
DNA=1.608 M, R2=0.967; EC50 circular DNA topoisomer=1.637 M, R2=0.993; pSyn: EC50 
circular & circular DNA topoisomer undefined; at 3-57 M one-way ANOVA for each 
concentration, p between <0.0001-0.0079; post-hoc Tukey tests shows no significant differences 
between two [circle vs. topoisomer] aSyn conditions p between 0.453-0.960, and two [circle vs. 
topoisomer] pSyn conditions p=0.252-0.956; there are significant differences between two [aSyn 
vs. pSyn] circle conditions p=0.001-0.028, and the two [aSyn vs. pSyn] topoisomer conditions 
p=<0.0001-0.002; 3-parameter dose-response curve, N=3 gels, x-axis synuclein concentrations 
on log scale). 
 
Figure 7. Mutant alpha-synuclein and beta- and gamma-synuclein do not bind DNA like 
wildtype alpha-synuclein. (A1) Left: Increasing concentrations of wildtype (WT) alpha-
synuclein (aSyn) and disease-causing point mutations (A30P, E46K, A53T) shift 300 bp DNA to 
higher apparent lengths, with A30P and A53T aSyn being less efficient at shifting than WT, and 
E46K being more efficient and shifting to a higher apparent length than WT. Right: Deletion of 
the central aggregation-prone NAC domain of aSyn (deltaNAC) increases the efficiency of 
shifting but reduces the apparent length of the shifted species compared to WT. (A2) Coomassie 
stain showing aSyn proteins loaded into each lane. (A3) DNA gel (green) and Coomassie stain 
(red) localization from the same experiment. (A4) Group data showing shifted fraction as a 
function of aSyn concentration (aSyn R2: WT=0.980, A30P=0.963, E46K=0.999, A53T=0.965; 
shifted fraction 1.4 uM aSyn: WT=0.550±0.082, A30P=0.270±0.047, E46K=0.975±0.028, 
A53T=0.379±0.102; shifted fraction 2.9 uM aSyn: WT=0.743±0.049, A30P=0.515±0.074, 
E46K=0.996±0.007, A53T=0.611±0.010; at 1.4 uM one-way ANOVA p<0.0001; post-hoc 
Tukey tests WT vs. A30P, E46K, A53T all p between 0.0002-0.0449; at 2.9 uM one-way 
ANOVA p<0.0001; post-hoc Tukey tests WT vs. A30P, E46K, A53T all p between 0.0004-
0.0174; shifted fraction 1.4 uM aSyn: WT=0.597±0.148, deltaNAC=1.000±0.000; shifted 
fraction 2.9 uM aSyn: WT=0.764±0.113, deltaNAC=1.000±0.000; at 1.4 uM t-test p=0.0092; at 
2.9 uM t-test p=0.0225; 3-parameter dose-response curve; N=3 gels, x-axis aSyn concentrations 
on log scale). (B1) Increasing aSyn concentration produces a shift of 300 bp DNA to an apparent 
length of ~600 bp, while beta-synuclein (bSyn) and gamma-synuclein (gSyn) produce no such 
shift. (B2) Coomassie stain showing synuclein proteins loaded into each lane. (B3) DNA gel 
(green) and Coomassie stain (red) localization from the same experiment. (B4) Group data 
showing shifted fraction as a function of synuclein concentration (aSyn R2=0.791; shifted 








bSyn & gSyn concentrations produced an undetectable shift =0.0; at 29 uM one-way ANOVA 
p=0.0087; post-hoc Tukey test aSyn vs. bSyn, and aSyn vs. gSyn p=0.0139; at 57 uM one-way 
ANOVA p=0.0010; post-hoc Tukey test aSyn vs. bSyn, and aSyn vs. gSyn p=0.0017; 3-
parameter dose-response curve; N=3 gels, x-axis Syn concentrations on log scale).  
 
Figure 8. Model of alpha-synuclein binding to double-stranded DNA and the potential 
similarities between this DNA binding and binding to phospholipid vesicles. (A) Single 
image from an animation (see Supplemental Fig. 7 for full animation) showing a model of aSyn 
bound to DNA. The aSyn coordinates come from previous work showing its structure bound to a 
phospholipid micelle (40). The two curved alpha-helices of the N-terminal domain of aSyn fit 
into consecutive major grooves of B form DNA. Lysine residues within the protein are labeled. 
The C-terminal domain, containing the serine-129 phosphorylation site, is poorly resolved in 
previous structural work, so it is not clear how this phosphorylation may modulate DNA binding. 
(B) Single image from an animation (see Supplemental Fig. 8 for full animation) showing a 
model of aSyn bound to DNA with 12 lysine residues labeled, using the same structural 
coordinates as in (A). In this particular model, potential electrostatic interactions between lysine-
21, -23, and -80 with the phosphate backbone of DNA are present. (C) Left: ~30 nm (in 
diameter) phospholipid vesicle shown in the presence of no synuclein, low or high alpha-
synuclein (aSyn), and high serine-129 phosphorylated alpha-synuclein (pSyn). At low aSyn 
concentrations, aSyn binds the vesicle given its relatively high affinity for these structures. At 
high aSyn concentrations, multiple aSyn molecules are bound. To our knowledge, the effects of 
serine-129 phosphorylation on the interaction of aSyn with phospholipid bilayer vesicles with a 
diameter of ~30 nm has not yet been tested. We speculate that serine-129 phosphorylation may 
inhibit binding in this context. Middle: 300 bp circular DNA having a diameter of ~30 nm. At 
low concentrations, aSyn binds DNA given its high affinity for the curved negatively charged 
DNA surface (due to the phosphate backbone). At high aSyn concentrations, multiple aSyn 
molecules are bound, analogous to their binding to phospholipid vesicle membranes of similar 
geometry (left). Serine-129 phosphorylation inhibits the ability of synuclein to bind 300 bp 
circular DNA. Right: 300 bp linear DNA having a length of ~100 nm. At low aSyn 
concentrations, aSyn binds as a monomer and bends linear DNA. At high aSyn concentrations, 
multiple aSyn molecules bind linear DNA and bend it into a conformation that resembles a DNA 
circle (middle). At high pSyn concentrations, pSyn binds as a monomer and bends linear DNA, 
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